knowledge -WSS

knowledge

author：comprehensive 2025-10-01 21:35:55 - browse：5144

light shines behind Pfizer CEO Albert Bourla as he attends a ceremony in Greece — Pfizer CEO Albert Bourla Giannis Papanikos/AP

Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer are the solution.

Shares in the drugmaker fell 44% last year, and it now has a market capitalization of only $150 billion — a quarter that of Eli Lilly and half that of longtime rival Merck. In March of last year the company announced that it would spend $43 billion to buy Seagen, a maker of a hot category of oncology medicines called antibody-drug conjugates. Pfizer’s shares have slumped another 9% so far this year. On Thursday, executives are holding an investor briefing to try to convince shareholders that its bet will pay off.

In an interview with STAT, Pfizer CEO Albert Bourla was insistent that the deal’s potential is being missed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Ukraine and a new approach to mental health in war

knowledge

hotspot

WSS

Allen Institute goes after foundational questions, CEO Costa says

Allen Institute goes after foundational questions, CEO Costa says

It's been 20 years since Dolly the sheep. Where's my clone?

Allen Institute goes after foundational questions, CEO Costa says

Readout LOUD podcast: possible new ALS drug, artificial wombs

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

hotspot

knowledge

leisure time

Walensky prepares to leave CDC — and Congress — behind

Allen Institute goes after foundational questions, CEO Costa says

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

JPM pitch from hospitals? Revenue streams outside of patient care

Walensky prepares to leave CDC — and Congress — behind

Study suggests new cause of Down syndrome: cells linked to aging

DIEP, the 'gold standard' of breast reconstruction, is under threat

Life science postdocs should get big pay hike, NIH panel says

Malaria cases in Florida and Texas: Here’s what you need to know

STAT Virtual Event: JPM Recap, Live!

focus

Boston Scientific acquires urology company Axonics for $3.7 billion

Stories you might have missed in 2023: health, science, medicine

At JPM 2024, hospital systems pitch financial strength to investors

Hearing on Medicare drug price negotiation gets unusually heated

Why are Kaiser Permanente staff considering a strike?

Experts study whether long Covid risk adds up with each reinfection

focus

knowledge

hotspot

entertainment